NF2 BioSolutions

Thanks to the generosity of our community, we have reached our $300,000 Rare Disease Day goal. This milestone allows us to begin the first phase of AAV9 NF2 gene therapy manufacturing. The first step in the manufacturing process is creating the DNA blueprint, called the plasmid.

Recording available now! For those who missed it or would like to watch again, the "Understanding NF2-SWN Today" webinar recording is now available. Here is the link: buff.ly/y4N6DhV

VS are the most common tumors in NF2, affecting the nerves responsible for hearing, facial expression and balance. While about 1 in 2,000 people develops a vestibular schwannoma, 95% of cases are not caused by NF2 We are advancing gene therapy forward to change that. Donate today

NF2 can cause complete hearing loss in both ears and affects about 1 in 25,000 people. Yet worldwide, 466 million people live with disabling hearing loss. At NF2 BioSolutions, we are working to change that reality. Donate today: buff.ly/gPz9woX

Rare Disease Day is a global call to action for conditions too often overlooked. NF2 may be rare, but rare diseases affect 1 in 10 people worldwide. We are moving toward clinical trials and now need help to begin manufacturing our AAV9 NF2 gene therapy. Goal: $30,000 by Feb 28

Don't miss our webinar this Friday in recognition of Rare Disease Day! Registration is still open here: buff.ly/rStG47w English subtitles will be available during the transmission. The webinar will be recorded and published on our YouTube Channel "I Need a Cure".

Mark your calendars! We are only 4 days away from Rare Disease Day.

Don't miss out on the latest updates! The webinar will be recorded. If you cannot attend, register to receive the recording to your email. Click here to register: buff.ly/gSCc7iO

From patient stories to expert-led webinars and research updates, our YouTube channel brings together science, advocacy, and hope. 🎥 Subscribe to our YouTube Channel “I Need a Cure”: buff.ly/gQCXobR

Join the upcoming webinar "Understanding NF2-SWN Today". On Friday, February 27th, at 10 am ET, leading experts Gareth Evans and Scott Plotkin will discuss the genetics, clinical features, treatments, and current clinical trials. Click here to register: buff.ly/8LBHo7X

We’re proud to support a diverse portfolio of research projects focused on advancing treatments and tools for NF2. 📖 Read our most recent research update here: 🔗 buff.ly/CappoAA

We are incredibly grateful to NF2 Project APs for their Giving Tuesday donation. Your support directly advances AAV9 viral vector production. We are continuing to raise funds to fully support this critical work and welcome others to join us in moving this research forward.

We are deeply saddened to share the news of the passing of Margaret Reynolds, whose legacy and dedication to NF2 BioSolutions will be remembered with great respect.

We are deeply saddened to share that Grace Chang passed away peacefully on December 5, surrounded by her loving family. Grace was 46 years old, a bright light to all who knew her. She will be remembered for her kindness, her warmth, and the joy she brought. Rest in peace, Grace.

The NF2 patient community at the Neurofibromatosis Shenzhen Care Center in China came together this Giving Tuesday to raise $2,554 in support of NF2 BioSolutions. We are grateful for your generosity and support. Thank you for standing with us and helping advance NF2 research.

Donate from Canada: buff.ly/KKneK3G Donate from the UK: buff.ly/QHY3y4B buff.ly/Dwv8MlH

Learn more here: buff.ly/WWbY0oM Let’s make NF2 gene therapy a reality. Donate today: Donate from the US: buff.ly/bHkHIW6 Donate using PayPal: buff.ly/GPDnUBh Donate from Europe with local tax benefits: buff.ly/lx0cDvi

In the 6th installment of our Gene Therapy Successes series, we move away from family-led successes to highlight our friend and acquaintance, Len Pattenden. We would like to congratulate Len and the entire Wiscott-Aldrich community on receiving FDA approval for their gene therapy